Therapeutics of 5-HT3 receptor antagonists: Current uses and future directions
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
The 5-Hydroxytryptamine3 (5-HT3) receptor is a member of the cys-loop family of ligand gated ion channels, of which the nicotinic acetylcholine receptor is the prototype. All other 5-HT receptors identified to date are metabotropic receptors. The 5-HT3 receptor is present in the central and peripheral nervous systems, as well as a number of non-nervous tissues. As an ion channel that is permeable to the cations, Na+, K+, and Ca2+, the 5-HT3 receptor mediates fast depolarizing responses in pre- and post-synaptic neurons. As such, 5-HT3 receptor antagonists that are used clinically block afferent and efferent synaptic transmission. The most well established physiological roles of the 5-HT3 receptor are to coordinate emesis and regulate gastrointestinal motility. Currently marketed 5-HT3 receptor antagonists are indicated for treatment of chemotherapy, radiation, and anesthesia-induced nausea and vomiting, as well as irritable bowel syndrome. Other therapeutic uses that have been explored include pain and drug addiction. The 5-HT3 receptor is one of a number of receptors that play a role in mediating nausea and vomiting, and as such, 5-HT3 receptor antagonists demonstrate greatest anti-emetic efficacy when administered in combination with other drug classes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lesch, K.-P., Bengel, D., Heils, A., Sabol, S. Z., Greenberg, B. D., Petri, S., Benjamin, J., Müller, C. R., Hamer, D. H., & Murphy, D. L. (1996) · Science · doi:10.1126/science.274.5292.1527 · Cited by 5,162
The functional gastrointestinal disorders and the Rome III process
Drossman, D. A. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.03.008 · Cited by 2,416
Low level of response to alcohol as a predictor of future alcoholism
(1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.2.184 · Cited by 826 · cited 1×
“Decreased sensitivity to ethanol in humans has been shown to correlate with a higher alcohol consumption and greater risk for alcoholism (Schuckit, 1994).”
BackgroundAn Evidence-Based Position Statement on the Management of Irritable Bowel Syndrome
American College of Gastroenterology IBS Task Force (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2008.122 · Cited by 694
Beene, D. L., Brandt, G. S., Zhong, W., Zacharias, N. M., Lester, H. A., & Dougherty, D. A. (2002) · Biochemistry · doi:10.1021/bi020266d · Cited by 300
Aggarwal, A., Cutts, T. F., Abell, T. L., Cardoso, S., Familoni, B., Bremer, J., & Karas, J. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90753-6 · Cited by 297
Ford, A. C., Brandt, L. J., Young, C., Chey, W. D., Foxx-Orenstein, A. E., & Moayyedi, P. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2009.223 · Cited by 261 · cited 20×
“The Rome guidelines, developed and refined over a period of years (Drossman, 1999; Drossman and Dumitrascu, 2006), define criteria by which IBS is diagnosed.”
BackgroundInfluentialAn Evidence-Based Systematic Review on the Management of Irritable Bowel Syndrome
Brandt, L. J., Chey, W. D., Foxx-Orenstein, A. E., Quigley, E. M. M., Schiller, L. R., Schoenfeld, P. S., Spiegel, B. M., Talley, N. J., & Moayyedi, P. (2009) · American Journal of Gastroenterology · doi:10.14309/00000434-200901001-00002 · Cited by 225 · cited 2×
“N IH -PA Author M anuscript N IH -PA Author M anuscript N IH -PA Author M anuscript absorbable antibiotics, selective C-2 chloride channel activators, 5-HT selective re-uptake inhibitors, 5-HT4 receptor agonists, and 5-HT3 receptor antagonists (Mertz, 2003; Brandt et al., 2009).”
BackgroundTreatment of nausea and vomiting: Gaps in our knowledge
Sanger, G. J., & Andrews, P. L. R. (2006) · Autonomic Neuroscience · doi:10.1016/j.autneu.2006.07.009 · Cited by 209
Vucurovic, K., Gallopin, T., Ferezou, I., Rancillac, A., Chameau, P., van Hooft, J. A., Geoffroy, H., Monyer, H., Rossier, J., & Vitalis, T. (2010) · Cerebral Cortex · doi:10.1093/cercor/bhp310 · Cited by 139 · cited 2×
“…67 promoter, has been used to demonstrate 5-HT3 receptor expression in vasoactive intestinal peptide and neuropeptide Y containing interneurons in the somatosensory cortex (Vucurovic et al., 2010) and in GABAergic neurons in the spinal superficial dorsal horn (Fukushima et al., 2009), respectively.”
Background
Cited by
Ma, N., & Ma, X. (2019) · Comprehensive Reviews in Food Science and Food Safety · doi:10.1111/1541-4337.12401 · Cited by 274
Barnes, N. M., Ahern, G. P., Becamel, C., Bockaert, J., Camilleri, M., Chaumont-Dubel, S., Claeysen, S., Cunningham, K. A., Fone, K. C., Gershon, M., et al. (2021) · Pharmacological Reviews · doi:10.1124/pr.118.015552 · Cited by 263
Bhatt, S., Devadoss, T., Manjula, S. N., & Rajangam, J. (2021) · Current Neuropharmacology · doi:10.2174/1570159x18666201015155816 · Cited by 119
“In addition to 5-HT, the 5-HT3 (hetero) receptors located on nerve terminals modulate the release of other NTs such as NE, DA, Ach and GABA [68].”
BackgroundInfluentialSerotonin and molecular neuroimaging in humans using PET
Saulin, A., Savli, M., & Lanzenberger, R. (2012) · Amino Acids · doi:10.1007/s00726-011-1078-9 · Cited by 113
Metadata
- Authors
- Machu, T. K.
- Venue
- Pharmacology & Therapeutics
- Publisher
- Elsevier BV
- Published
- 2011-06
- Volume
- 130
- Issue
- 3
- Pages
- 338-347
- ISSN
- 0163-7258 (ISSN-L)
- OpenAlex
- W2049652736
- Cited by
- 123
- References
- 11
- FWCI
- 6.63
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Therapeutics of 5-HT3 receptor antagonists: Current uses and future directions. https://app.cochat.ai/papers/10.1016/j.pharmthera.2011.02.003
- The paper
- Machu, T. K. (2011). Therapeutics of 5-HT3 receptor antagonists: Current uses and future directions. Pharmacology & Therapeutics. https://doi.org/10.1016/j.pharmthera.2011.02.003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.